ARTIMPLANT YEAR-END REPORT JANUARY - DECEMBER 2009

ARTIMPLANT YEAR-END REPORT JANUARY - DECEMBER 2009

Västra Frölunda, Sweden, February 11 2010

• Net revenue for the fourth quarter increased to SEK 5.8 million (4.6) and
doubled for the full year to SEK 24.0 million (12.1)*
• The net loss for the fourth quarter improved to SEK 5.4 million (6.0) and for
the full year the net loss improved to SEK 18.6 million (22.6)   
• Earnings per share for the fourth quarter improved to SEK -0.09 (-0.10) and
for the full year SEK -0.31 (-0.38)  
• Product sales to end-customers and distributors multiplied to SEK 8.7 million
(1.7) for the full year, equivalent to 37% (15) of product sales 
• Sales of Artelon® Spacer for the fourth quarter amounted to SEK 2.4 million
(3.1) and for the full year sales rose to SEK 13.1 million (7.4)
• Sales of Artelon® Tissue Reinforcement for the fourth quarter increased to SEK
3.3 million (1.6) and for the full year to SEK 10.2 million (4.1)   
• Goal to reach positive cash flow before changes in working capital, at a
monthly basis, towards the end of 2010
• The Board proposes that no dividend be paid for 2009

N.B. This is a translation from Swedish. The Swedish version shall always take
precedence.

Artimplant will hold a telephone conference by reason of this report on February
11, 2010 at 11 am (CET). For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information is available at www.artimplant.com. To subscribe to future
press releases please go to
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant's mission is to restore the health of patients by offering medical
professionals degradable implants that help the body to heal.

Artimplant is a medical technology company that restores health through the
development, production and marketing of degradable implants that regenerate
body functions and improve quality of life. Our products are made from Artelon®,
a biomaterial developed by the Company. Artimplant produces implants for the
treatment of osteoarthritis in hands and feet, shoulder and other soft tissue
injuries as well as oral and veterinary applications. The Company's products are
sold through licensees and own sales under Artimplant's brand take place through
agents and distributors. 

Artimplant is a public company listed on the NASDAQ OMX Stockholm in the Small
Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on February 11 2010 at 8:45 AM (CET).